<DOC>
	<DOCNO>NCT00612209</DOCNO>
	<brief_summary>This open label , single arm , dose escalation study ARQ 197 patient advance solid tumor .</brief_summary>
	<brief_title>A Phase 1 Study ARQ 197 Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Patients take ARQ 197 orally twice daily continuously dose level specify respective dose cohort . The ARQ 197 start dose total daily dose 200 mg ( 100 mg bid ) . ARQ 197 treatment continue progression disease , unacceptable toxicity , another discontinuation criterion meet . In case toxicity , dose adjustment permit . A treatment cycle design four week ( 28 day ) repeat without therapy interruption .</detailed_description>
	<criteria>Signed write informed consent must obtain document accord ICH GCP , local regulatory requirement , permission use private health information accordance HIPPA prior studyspecific screen procedure A histologically cytologically confirm advanced solid tumor , include 10 patient advanced prostate cancer expansion cohort . ≥ 18 year age . Patients must accessible tumor safely amenable tumor biopsy . Measurable disease define Response Evaluation Criteria Solid Tumors Tumor imageable DCEMRI preferably &gt; 3cm abdomen , pelvis , head/neck peripheral limb ( 12 patient undergoing MRI study include DCEMRI DWMRI expand cohort ) Karnofsky performance status ( KPS ) ≥ 70 % Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last ARQ 197 dose Females childbearing potential must negative serum pregnancy test Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) ≤ 5.0 × ULN metastatic liver disease Hemoglobin ≥ 10 g/dl Total bilirubin ≤ 1.5 × ULN Creatinine ≤ 1.5 x ULN Absolute neutrophil count ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L The following inclusion criterion apply patient prostate cancer : Histologically document adenocarcinoma prostate , clinically refractory resistant hormone therapy , document progression follow castration PSA radiological evidence progressive prostate cancer Ongoing gonadal androgen deprivation therapy LHRH analogues orchiectomy . Patients orchiectomy must maintain effective LHRH analogue therapy trial . Castrate testosterone level [ &lt; 50 ng/dL &lt; 2.00 nmol/L ( nmol/L x 28.8 = ng/dL ) ] Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within four week prior first dose ARQ 197 Surgery within 4 week prior first dose Known untreated brain metastasis Pregnant breastfeed Significant gastrointestinal disorder ( ) , opinion Principal Investigator , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric resection ) Unable unwilling swallow ARQ 197 capsule twice daily Uncontrolled intercurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement For patient undergoing magnetic resonance imaging ( MRI ) study ( include DCEMRI DWMRI ) expand cohort : Contraindications MRI , e.g . contraindicate metal implant Patients Creatinine &gt; x1 ULN Patients without antecubital fossa venous access</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ARQ 197 , advance solid tumor , phase 1 , dose escalation , pharmacodynamics , safety</keyword>
</DOC>